Oncology Institute Company Top Insiders
TOI Stock | USD 0.16 0.01 5.88% |
Oncology Institute's insiders are aggressively selling. The analysis of insiders' sentiment of trading Oncology Institute stock suggests that almost all insiders are panicking at this time. Oncology Institute employs about 800 people. The company is managed by 19 executives with a total tenure of roughly 1867 years, averaging almost 98.0 years of service per executive, having 42.11 employees per reported executive.
Oncology Institute's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-01-29 | Havencrest Healthcare Partners | Disposed 8637 @ 2.12 | View | ||
2024-01-26 | Havencrest Healthcare Partners | Disposed 6979 @ 2.14 | View | ||
2024-01-24 | Havencrest Healthcare Partners | Disposed 24915 @ 2.3 | View | ||
2024-01-22 | Havencrest Healthcare Partners | Disposed 10263 @ 2.12 | View | ||
2024-01-19 | Havencrest Healthcare Partners | Disposed 11986 @ 2.13 | View |
Monitoring Oncology Institute's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Oncology |
Oncology Institute Management Team Effectiveness
The company has Return on Asset of (0.1942) % which means that on every $100 spent on assets, it lost $0.1942. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.2559) %, meaning that it generated no profit with money invested by stockholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.47. The current Return On Capital Employed is estimated to decrease to -0.46. As of now, Oncology Institute's Asset Turnover is decreasing as compared to previous years.The Oncology Institute's current Net Income Applicable To Common Shares is estimated to increase to about 64.3 K, while Common Stock Shares Outstanding is projected to decrease to under 68.4 M.
Oncology Institute Workforce Comparison
Oncology Institute is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 676,400. Oncology Institute adds roughly 800 in number of employees claiming only tiny portion of equities under Health Care industry.
Oncology Institute Profit Margins
The company has Net Profit Margin of (0.2) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.22 | 0.1837 |
|
|
Oncology Institute Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Oncology Institute insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hively Brad six days ago Acquisition by Hively Brad of 44000 shares of Oncology Institute subject to Rule 16b-3 | ||
Podnos Yale over a week ago Disposition of 1026 shares by Podnos Yale of Oncology Institute at 0.136 subject to Rule 16b-3 | ||
Virnich Daniel over two weeks ago Disposition of 117142 shares by Virnich Daniel of Oncology Institute subject to Rule 16b-3 | ||
Podnos Yale over three months ago Disposition of 1860 shares by Podnos Yale of Oncology Institute at 2.385 subject to Rule 16b-3 | ||
Shah Mihir over three months ago Acquisition by Shah Mihir of 151459 shares of Oncology Institute subject to Rule 16b-3 | ||
Hively Brad over three months ago Disposition of 18121 shares by Hively Brad of Oncology Institute at 0.4578 subject to Rule 16b-3 | ||
Hively Brad over three months ago Disposition of 19526 shares by Hively Brad of Oncology Institute at 0.5753 subject to Rule 16b-3 | ||
Virnich Daniel over six months ago Acquisition by Virnich Daniel of 198517 shares of Oncology Institute subject to Rule 16b-3 |
Oncology Institute Notable Stakeholders
An Oncology Institute stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncology Institute often face trade-offs trying to please all of them. Oncology Institute's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncology Institute's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Julie Korinke | Director Communications | Profile | |
FACHE MD | Chief Officer | Profile | |
Mark Esq | General Counsel | Profile | |
Rob Carter | Senior Finance | Profile | |
Bradford Hively | CEO Director | Profile | |
Rakesh MBA | Director Technology | Profile | |
Laura Szitar | Chief Officer | Profile | |
Richard Barasch | Executive Board | Profile | |
Jeremy MBA | Chief Officer | Profile | |
Diona CPA | Principal Officer | Profile | |
MBA JD | Senior Compliance | Profile | |
FACHE MBA | President | Profile | |
Philip Reger | Chief Officer | Profile | |
MD MBA | Chief Officer | Profile | |
Hilda MBA | Founder Officer | Profile | |
Mihir CPA | Chief Officer | Profile | |
Jordan McInerney | Chief Officer | Profile | |
Richy MD | Founder Officer | Profile | |
FACS MD | Chief Practice | Profile |
About Oncology Institute Management Performance
The success or failure of an entity such as Oncology Institute often depends on how effective the management is. Oncology Institute management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncology management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncology management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.45) | (0.47) | |
Return On Capital Employed | (0.44) | (0.46) | |
Return On Assets | (0.40) | (0.38) | |
Return On Equity | (1.46) | (1.38) |
Oncology Institute Workforce Analysis
Traditionally, organizations such as Oncology Institute use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncology Institute within its industry.Oncology Institute Manpower Efficiency
Return on Oncology Institute Manpower
Revenue Per Employee | 405.3K | |
Revenue Per Executive | 17.1M | |
Net Loss Per Employee | 103.8K | |
Net Loss Per Executive | 4.4M | |
Working Capital Per Employee | 135.9K | |
Working Capital Per Executive | 5.7M |
Complementary Tools for Oncology Stock analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Transaction History View history of all your transactions and understand their impact on performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |